Earnings summaries and quarterly performance for Alector.
Executive leadership at Alector.
Board of directors at Alector.
Research analysts who have asked questions during Alector earnings calls.
Myles Minter
William Blair & Company
3 questions for ALEC
Also covers: ARCT, ARGX, AXSM +11 more
Alec Stranahan
Bank of America
2 questions for ALEC
Also covers: AGIO, BTAI, DAWN +11 more
Ananda Ghosh
H.C. Wainwright & Co.
2 questions for ALEC
Also covers: ABOS, AMLX, PEPG +1 more
Carter L. Gould
Barclays
2 questions for ALEC
Also covers: ABBV, AMGN, BMY +7 more
Jeff Hung
Morgan Stanley
2 questions for ALEC
Also covers: ACAD, BHVN, BLUE +10 more
Pete Stavropoulos
Cantor Fitzgerald
2 questions for ALEC
Also covers: ABOS, ARCT, AXSM +7 more
Thomas Shrader
BTIG
2 questions for ALEC
Also covers: ABOS, ARCT, CMPS +8 more
Yaron Werber
TD Cowen
2 questions for ALEC
Also covers: AMGN, ARGX, ASND +14 more
Corinne Jenkins
Goldman Sachs
1 question for ALEC
Also covers: ACRS, ATHA, FULC +5 more
Douglas Macpherson
Mizuho Securities
1 question for ALEC
Also covers: QSI, XFOR
Emily
Stifel
1 question for ALEC
Graig Suvannavejh
Mizuho Securities
1 question for ALEC
Also covers: ADAP, ADVM, AMLX +11 more
Julian Pino
Jefferies
1 question for ALEC
Also covers: ACAD, ALNY, BMRN +2 more
Michael Riad
Morgan Stanley
1 question for ALEC
Also covers: ACAD, ITCI, JAZZ +3 more
Samantha Schaeffer
Cantor Fitzgerald
1 question for ALEC
Also covers: ARCT
Sarah Schram
William Blair
1 question for ALEC
Also covers: XENE
Steven Ayanov
TD Securities
1 question for ALEC
Tom Shrader
BTIG
1 question for ALEC
Also covers: ABOS, ALDX, ESPR +4 more
Recent press releases and 8-K filings for ALEC.
Alector Reports Q3 2025 Financial Results and Strategic Business Updates
ALEC
Earnings
Layoffs
Guidance Update
- Alector reported a net loss of $34.7 million, or $0.34 per share, for the third quarter of 2025. As of September 30, 2025, the company had $291.1 million in cash, cash equivalents, and investments, which is anticipated to fund operations through 2027.
- In October 2025, Alector implemented a reduction in force of approximately 47% to focus resources and extend its cash runway.
- The company is advancing lead candidates AL137 and AL050 toward IND-enabling studies, targeting IND submissions in 2026 and 2027, respectively.
- Topline results from the Phase 3 clinical trial for latozinemab in frontotemporal dementia due to a GRN gene mutation did not demonstrate clinical benefit, leading to the discontinuation of the trial. An independent interim analysis for the PROGRESS-AD Phase 2 clinical trial of nivisnebart is planned for the first half of 2026.
Nov 6, 2025, 9:12 PM
Alector Reports Third Quarter 2025 Financial Results and Business Updates
ALEC
Earnings
Layoffs
Guidance Update
- Alector reported a net loss of $34.7 million, or $0.34 per share, for the third quarter ended September 30, 2025, with collaboration revenue of $3.3 million.
- The company's cash, cash equivalents, and investments totaled $291.1 million as of September 30, 2025, providing a runway through 2027.
- Alector is advancing lead candidates AL137 and AL050 toward IND-enabling studies, with IND filings targeted for 2026 and 2027, respectively, and an independent interim analysis for the PROGRESS-AD Phase 2 clinical trial of nivisnebart (AL101) is planned for 1H 2026.
- In October 2025, the company implemented a workforce reduction of approximately 47% and discontinued the INFRONT-3 Phase 3 clinical trial for latozinemab due to a lack of clinical benefit.
Nov 6, 2025, 9:05 PM
Alector Announces Negative Phase 3 Clinical Trial Results for Latozinemab
ALEC
New Projects/Investments
- Biotechnology company Alector announced that its drug, latozinemab, failed to meet safety and efficacy criteria in a Phase 3 clinical trial for cases of FTD caused by a GRN gene variant.
- While the treatment resulted in a significant increase in plasma PGRN levels, it did not slow the progression of the disease as measured by clinical co-primary endpoints or affect biological markers of disease progression.
- Based on these results, Alector has concluded the study, and the open-label extension portion of the trial and the continuation study will both be discontinued.
Oct 21, 2025, 10:45 PM
Alector's Latozinemab Phase 3 Trial Fails to Meet Primary Endpoint
ALEC
Layoffs
Profit Warning
- Alector's Phase 3 INFRONT-3 trial for latozinemab, targeting frontotemporal dementia (FTD) caused by GRN gene mutations, failed to meet its primary clinical endpoint of slowing disease progression.
- Despite the drug significantly increasing plasma progranulin levels, it did not translate into clinical benefit or affect other biomarkers.
- In response to the trial failure, Alector announced it would terminate the open-label extension of the trial and lay off 49% of its 238 employees.
- The 96-week double-blind study, conducted in collaboration with GSK, found the treatment to be safe with no major adverse events reported.
Oct 21, 2025, 9:53 PM
Alector Announces Latozinemab Phase 3 Trial Results and Business Update
ALEC
Layoffs
Management Change
Guidance Update
- Alector announced that its latozinemab (AL001) Phase 3 INFRONT-3 clinical trial for frontotemporal dementia due to a GRN mutation did not meet its clinical co-primary endpoint, leading to the discontinuation of the open-label extension and continuation studies for latozinemab.
- To align resources with strategic priorities, Alector is implementing a workforce reduction of approximately 49%, impacting about 75 employees.
- Total incremental restructuring charges associated with the reduction in force are expected to be approximately $7.7 million, with cash payments anticipated in the first half of 2026.
- The company estimates it had approximately $291.1 million in cash, cash equivalents, and short-term investments as of September 30, 2025, which is expected to provide a financial runway through 2027.
- Sara Kenkare-Mitra, Ph.D., President and Head of Research and Development, will resign from her role effective December 22, 2025.
Oct 21, 2025, 8:08 PM
ALEC Holdings Debuts on DFM After $381M IPO
ALEC
Dividends
New Projects/Investments
- ALEC Holdings debuted on the Dubai Financial Market (DFM) following the UAE's largest construction sector IPO, raising approximately $381 million through the sale of 20% of its share capital.
- The IPO was heavily oversubscribed, with demand reaching around $8.1 billion, more than 21 times the offering size, and attracted high non-UAE investor participation.
- The company, majority-owned by the Investment Corporation of Dubai (ICD) which retains an 80% stake, has a significant project backlog of AED 35.4 billion.
- ALEC Holdings plans to distribute substantial dividends starting in 2026, with a minimum payout ratio of 50 percent of net profit, paid biannually in April and October.
- On its debut day, shares opened at 1.47 dirhams and traded as high as 1.50 dirhams, closing slightly above the IPO price, reflecting strong investor interest.
Oct 15, 2025, 7:13 AM
Alector Provides Update on Progranulin Franchise and Brain Carrier Programs
ALEC
Guidance Update
New Projects/Investments
- Alector expects top-line Phase 3 data for latazimumab in Frontotemporal Dementia (FTD GRN) by mid-Q4 2025. This drug has received breakthrough therapy, fast track, and orphan drug designation.
- The company's partnership with GSK for its progranulin elevating franchise includes $700 million in upfront payments and up to $1.5 billion in potential development and commercial milestones.
- Nivisibart, developed in collaboration with GSK for Alzheimer's disease, has completed enrollment in its Phase 2 trial, with an independent interim analysis expected in 2026.
- Alector is advancing its proprietary Elektor Brain Carrier (ABC) technology, targeting first-in-human trials in 2026 for its ABC-enabled anti-amyloid beta antibodies (AL037 and AL137) for Alzheimer's disease, and 2027 for its ABC-enabled GK's enzyme replacement therapy (AL050) for Parkinson's disease.
Sep 22, 2025, 4:00 PM
Quarterly earnings call transcripts for Alector.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more